Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor

Acta Oncologica

Volumn 55, Issue 3, 2016, Pages 329-340

  Sacré, Anne ^a   Barthé Lémy, Philippe ^b   Korenbaum, Clement ^b   Burgy, Mickael ^b   Wolter, Pascal ^a   Dumez, Herlinde ^a   Lerut, Evelyne ^a   Loyson, Tine ^c   Joniau, Steven ^a   Oyen, Raymond ^a   Debruyne, Philip R ^c,d   Schöffski, Patrick ^a   Beuselinck, Benoit ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c AZ GROENINGE   (Belgium)

^d UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AXITINIB; BIOLOGICAL MARKER; CALCIUM; EVEROLIMUS; LACTATE DEHYDROGENASE; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR; PROTEIN KINASE INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; FEMALE; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; KIDNEY NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84945152095     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1099731     Document Type: Article

References (30)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 2007;356:115-24.
2. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
3. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
4. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765-72.
5. Levy A, Menard J, Albiges L, Loriot Y, Di Palma M, Fizazi K, et al. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer 2013;49:1898-904.
6. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
7. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011;378:1931-9.
8. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol Epub 2013 Dec 2.
9. Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmuller C, et al. SWITCH: A randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenibsunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol 2015 May 4.
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116: 4256-65.
11. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8.
12. Beuselinck B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, et al. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: A retrospective analysis. Clin Genitour Cancer 2014;12:e205-14.
13. Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A, et al. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer 2012;48:1023-30.
14. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011;22: 794-800.
15. Vickers MM, Al-Harbi H, Choueiri TK, Kollmannsberger C, North S, MacKenzie M, et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: Results from the international metastatic renal cell carcinoma database consortium. Clin Genitour Cancer 2013;11:311-15.
16. Grassi P, Verzoni E, Mariani L, De Braud F, Coppa J, Mazzaferro V, et al. Prognostic role of pancreatic metastases from renal cell carcinoma: Results from an Italian center. Clin Genitour Cancer 2013;11:484-8.
17. Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, et al. Prognostic impact of baseline serum c-reactive protein in metastatic renal cell carcinoma patients treated with sunitinib. BJU Int 2014;114:81-9.
18. Stenman M, Laurell A, Lindskog M. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Med Oncol 2014;31:841.
19. Yildiz I, Sen F, Kilic L, Ekenel M, Ordu C, Kilicaslan I, et al. Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma. Curr Oncol 2013;20:e546-53.
20. Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Stat Med 2005;15: 361-87.
21. Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: Subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014;110:2821-8.
22. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, et al. The association of clinical outcome to firstline VEGF-targeted therapy with clinical outcome to second-line VEGFtargeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013;8:203-9.
23. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: A population-based study. Lancet Oncol 2015;16:293-300.
24. Beutner U, Leowardi C, Bork U, Luthi C, Tarantino I, Pahernik S, et al. Survival after renal cell carcinoma metastasis to the thyroid: Single center experience and systematic review of the literature. Thyroid 2015;25:314-24.
25. Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res 2015;21:1329-39.
26. Di Lorenzo G, Carteni G, Autorino R, Bruni G, Tudini M, Rizzo M, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27:4469-74.
27. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
28. Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010;76:430-4.
29. Mackenzie MJ, Rini BI, Elson P, Schwandt A, Wood L, Trinkhaus M, et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol 2011;22:145-8.
30. Porta C, Procopio G, Carteni G, Sabbatini R, Bearz A, Chiappino I, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): An Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011; 108(8 Pt 2):E250-7.